FDA approves crizotinib for children and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma
![Pfizer](https://flasco.org/wp-content/uploads/img-postthumb-pfizer.png)
On January 14, 2021, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. More Information: